Profibrotic and Angiogenic Factors in Asthma

Inflammation and Allergy Drug Design

Volumn , Issue , 2011, Pages 237-252

  Berkman, Neville ^a   Levi Schaffer, Francesca ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Airway hyperresponsiveness (AHR) component of asthma, optimal anti inflammatory therapy; Airway remodeling, prominent pathophysiologic feature of chronic asthma; Asthma and airway fibrosis increase in fibroblasts, differentiation of myofibroblasts in asthma; Attenuation of angiogenesis and cancer therapies, VEGF pathway as key regulator of angiogenesis; Eosinophils and angiogenesis eosinophil contribution to angiogenesis, in asthma; Interleukin 4 and interleukin 13 cytokines from Th2 cells, mediators in asthma; Nerve growth factor (NGF), important neurotrophic agent produced in airways; Profibrotic and angiogenic factors in asthma; Transforming growth factor beta critical for embryogenesis and tissue repair, role in mediating immune responses; Transforming growth factor beta TGF superfamily, over 30 different proteins and BMPs

Indexed keywords

EID: 84856475829     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444346688.ch19     Document Type: Chapter

References (159)

1. Davies DE, Wicks J, Powell RM, et al. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003; 111: 215-25.
2. Homer RJ, Elias JA. Airway remodeling in asthma: therapeutic implications of mechanisms. Physiology (Bethesda) 2005; 20: 28-35.
3. Homer RJ, Elias JA. Consequences of long-term inflammation. Airway remodeling. Clin Chest Med 2000; 21: 331-43.
4. McMillan SJ, Lloyd CM. Prolonged allergen challenge in mice leads to persistent airway remodeling. Clin Exp Allergy 2004; 34: 497-507.
5. Benayoun L, Druilhe A, Dombert MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167: 1360-8.
6. Boxall C, Holgate ST, Davies DE. The contribution of transforming growth factor -ß and epidermal growth factor signalling to airway remodeling in chronic asthma. Eur Respir J 2006; 27: 208-29.
7. Pare PD, Roberts CR, Bai TR, Wiggs BJ. The functional consequences of airway remodeling in asthma. Monaldi Arch Chest Dis 1997; 52: 589-96.
8. Chu HW, Halliday JL, Martin RJ, et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998; 158: 1936-44.
9. Roberts CR, Burke AK. Remodeling of the extracellular matrix in asthma: proteoglycan synthesis and degradation. Can Resp J 1998; 5: 48-50.
10. Huang J, Olivenstein R, Taha R, Hamid Q, Ludwing M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am J Respir Crit Care Med 1999; 160: 725-9.
11. Johnson PR, Burgess JK, Ge Q, et al. Connective tissue growth factor induces extracellular matrix in asthmatic airway smooth muscle. Am J Respir Crit Care Med 2006; 173: 32-41.
12. Chan V, Burgess JK, Ratoff JC, et al. Extracellular matrix regulated enhanced eotaxin expression in asthmatic airway smooth muscle cells. Am J Respir Crit Care Med 2006; 174: 379-85.
13. Hirst SJ, Twort CH, Lee TH. Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype. Am J Respir Cell Mol Biol 2000; 23: 335-44.
14. Dekkers BG, Schaafsma D, Nelemans SA, Zaagsma J, Meurs H. Extracellular matrix proteins differentially regulate airway smooth muscle phenotype and function. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1405-L1413.
15. Henderson N, Markwick LJ, Elshaw SR, Freyer AM, Knox AJ, Johnson SR. Collagen 1 and thrombin activate MMP-2 by MMP-14 dependent and independent pathways: applications for airway smooth muscle migration. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1030-L1038.
16. Bonacci JV, Schuliga M, Harris T, Stewart AG. Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signaling. Br J Pharmacol 2006; 149: 365-73.
17. Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 2001; 187: 265-76.
18. Miyazono K, Ichijo H, Heldin Ch. Transforming growth factor-beta; latent forms, binding proteins and receptors. GRF 1993; 8: 11-22.
19. Khalil N. TGF-beta; from latent to active. Microbes Infect 1999; 1: 1255-63.
20. Bossé Y, Rola-Pleszczynski M. Controversy surrounding the increased expression of TGF -ß1 in asthma. Respir Res 2007; 8: 66.
21. Roberts AB, Tian F, Dacosta Byfield S, et al. Smad3 is key to TGF-ß-mediated epithelial to mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17: 19-27.
22. Shi Y, Massague J. Mechanisisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
23. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009; 19: 7188.
24. Kariyawasam HH, Pegorier S, Barkans J, et al. Activin and transforming growth factor -ß signaling pathways are activated after allergen challenge in mild asthma. J Allergy Clin Immunol 2009; 124: 454-62.
25. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta 1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-76.
26. Evans RA, Tian YC, Steadman R, Phillips AO. TGF-beta-1 mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res 2003; 282: 90-100.
27. Goldsmith AM, Bentley JK, Zhou L, et al. Transforming growth factor-beta induces airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol 2006; 34: 247-254.
28. Duvernelle C, Freund V, Frossard N. Transforming growth factor-beta and its role in asthma. Pulm Pharmacol Ther 2003; 16: 181-96.
29. Kalluri R, Neilson EG. Epithelial mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
30. Hackett TL, Warner SM, Stefanowicz D, et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor -ß1. Am J Respir Crit Care Med 2009; 180: 122-33.
31. Elovic AE, Ohyama H, Sauty A, et al. IL-4 dependent regulation of TGF, alfa and TGF beta 1 expression in human eosinophils. J Immunol 1998; 160: 6121-7.
32. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776-9.
33. Fattouh R, Jordana M. TGF -ß, eosinophils and IL-13 in allergic airway remodeling: A critical appraisal with therapeutic considerations. Inflamm Allergy Drug Targets 2008; 7: 224-36.
34. Minshall EM, Leung DY, Martin RJ, et al. Eosinophil-associated TGF-beta1 mRNA, expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997; 17: 326-33.
35. Ohno I, Nitta Y, Yamauchi K, et al. Transforming growth factor beta 1 (TGF-beta1) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1996; 15: 404-9.
36. Redington AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma/Measurement in bron-choalveolar lavage fluid. Am J Respir Crit Care Med 1997; 156: 642-7.
37. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 591-9.
38. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112: 1029-36.
39. Balzar S, Chu HM, Silkoff P, et al. Increased TGF-beta 2 in severe asthma with eosinophilia. J Allergy Clin Immunol 2005; 115: 110-17.
40. Chu HW, Balzar S, Seedorf GJ. Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma. Am J Pathol 2004; 165: 1097-106.
41. Ueda T, Niimi A, Matsumoto H, et al. TGFB1 promoter polymorphism C-509T, and pathophysiology of asthma. J Allergy Clin Immunol 2008; 121: 659-64.
42. Liebhart J, Polak M, Dabrowski A, et al. The G/G genotype of transforming growth factor beta 1 (TGF beta 1) single nucleotide polymorphism coincident with other host and environmental factors is associated with irreversible bronchoconstriction in asthmatics. Int J Immunogenet 2008; 35: 417-22.
43. Fattouh R, Midence NG, Arias K, et al. Transforming growth factor-beta regulated house dust mite-induced allergic airway inflammation but not airway remodeling. Am J Respir Crit Care Med 2008; 177: 593-603.
44. Kelly MM, Leigh R, Bonniaud P, et al. Epithelial expression of profibrotic mediators in a model of allergen induced airway remodeling. Am J Respir Cell Mol Biol 2005; 32: 99-107.
45. Karnar RK, Herbert C, Foster PS. Expression of growth factors by airway epithelial cells in a model of chronic asthma; regulation and relationship to subepithelial fibrosis. Clin Exp Allergy 2004; 34: 567-75.
46. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen induced airway remodeling by treatment with anti TGF-beta antibody: effect on the Smad signaling pathway. J Immunol 2005; 174: 5774-80.
47. Alcorn JF, Rinaldi LM, Jaffie EF, et al. Transforming growth factor beta1 suppresses airway hyperrespon-siveness in allergy disease. Am J Respir Crit Care Med 2007; 176: 974-982.
48. Le AV, Cho JY, Miller M, McElwain S, Golgotiu K, Broide DH. Inhibition of allergen induced airway remodeling in Smad 3 deficient mice. J Immunol 2007; 178: 7310-16.
49. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Ann Rev Immunol 1998; 16: 137-161.
50. Scherf W, Burdach S, Hansen G. Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model. Eur J Immunol 2005; 35: 198-206.
51. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546-56.
52. Wan YY, Flavell RA. Regulatory T cells, transforming growth factor-beta and immune suppression. Proc Am Thorac Soc 2007; 4: 271-6.
53. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-49.
54. Bosse Y, Thompson C, Stankova J, Rola-Pleszczynki M. Fibroblast growth factor 2 and transforming growth factor beta1 in human bronchial smooth muscle cell proliferation. Am J Respir Cell Moll Biol 2006; 34: 746-53.
55. Nugent MA, Iozzo RV. Fibroblast growth factor 2. Int J Biochem Cell Biol 2000; 32: 115-20.
56. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-7.
57. Redington AE, Roche WR, Madden J, et al. Basic fibrob-last growth factor in asthma; measurement in bron-choalveolar lavage fluid basally and following allergen challenge. J Allergy Clin Immunol 2001; 107: 384-7.
58. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor basic fibroblast growth factor and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001; 107: 295-301.
59. Jeon SG, Lee CG, Oh MH, et al. Recombinant basic fibroblast growth factor inhibits the airway hyperre-sponsiveness, mucus production and lung inflammation induced by an allergen challenge. J Allergy Clin Immunol 2007; 119: 831-7.
60. Fredriksson L, Li H, Eriksson U. The PDGF family: Four gene products from five dimeric isoforms. Cytokine Growth Factor Rev 2004; 15: 197-204.
61. Bach MK, Brashler JR, Stout BK, et al. Activation of human eosinophils by platelet-derived growth factor. Int Arch Allergy Immunol 1992; 97: 121-9.
62. Chanez P, Vignola M, Stenger R, Vic P, Michel FB, Bousquet J. Platelet derived growth factor in asthma. Allergy 1995; 50: 878-83.
63. Dube J, Chakir J, Laviolette M, et al. In vitro procollagen synthesis and proliferative phenotype of bronchial fibroblasts from normal and asthmatic subjects. Lab Invest 1998; 78: 297-307.
64. Lewis CC, Chu HW, Westcott JY, et al. Airway fibrob-lasts exhibit a synthetic phenotype in severe asthma. J Allergy Clin Immunol 2005; 115: 534-40.
65. Yamashita N, Sekine K, Miyasaka T, et al. Platelet-derived growth factor is involved in the augmentation of airway responsiveness through remodeling of airways in diesel exhaust particulate-treated mice. J Allergy Clin Immunol 2001; 107: 135-42.
66. Ingram JL, Rice AB, Geisenhoffer K, Madtes DK, Bonner JC. IL-13 and IL-1beta promote lung fibroblast growth through coordinated up-regulation of PDGF-AA and PDGF-R alpha. FASEB J 2004; 18: 1132-4.
67. Pegorier S, Arouche N, Dombret MC, Aubier M, Pretolani M. Augmented epithelial endothelin-1 expression in refractory asthma. J Allergy Clin Immunol 2007; 120: 1301-7.
68. Yahiaoui L, Villeneuve A, Valderrama-Carvajal H, Burke F, Fixman ED. Endothelin-1 regulates prolif-erative responses, both alone and synergistically with PDGF, in rat tracheal smooth muscle cells. Cell Physiol Biochem 2006; 17: 37-46.
69. Gawlik R, Jastrzebski D, Ziora D, Jarzab J. Concentration of endothelin in plasma and BALF fluid from asthmatic patients. J Physiol Pharmacol 2006; 57 (Suppl 4): 103-10.
70. Ehrenreich H, Burd PR, Rottem M, et al. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol 1992; 4: 147-56.
71. Knott PG, D'Aprile AC, Henry PJ, Hay DW, Goldie RG. Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol 1995; 114: 1-3.
72. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: A new and important player on the pathogenesis of fibrosis. Curr Rhematol Rep 2002; 4: 136-42.
73. Xie S, Sukar MB, Issa R, Oltanns U, Nicholson AG, Chung KF. Regulation of TGF beta 1 induced connective tissue growth factor expression in airway smooth muscle cells. Am J Physiol Luang Cell Mol Physiol 2005; 288: L68-L76.
74. Brigstock DR. Connective tissue growth factor (CCN2: CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal 2010; 4: 1-4.
75. Burgess JK, Johnson PR, Ge Q, et al. Expression of connective tissue growth factor in asthmatic airway smooth muscle cells. Am J Respir Crit Care Med 2003; 167: 71-7.
76. Burgess JK. The role of the extracellular matrix and specific growth factors in the regulation of inflammation and remodeling in asthma. Pharmacol Therap 2009; 122: 19-29.
77. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-6.
78. Amishima M, Munakata M, Nasuhara Y, et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Crit Care Med 1998; 157: 1907-12.
79. Jose PJ, Griffiths-Johnson DA, Collins PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea-pig model of allergic airways inflammation. J Exp Med 1994; 179: 881-7.
80. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Resp Cell Mol Biol 2001; 24: 682-7.
81. Puxeddu I, Bader R, Piliponsky AM Reich R, Levi-Schaffer F, Berkman N. The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. Allergy Clin Immunol 2006; 117: 103-10.
82. Kohan M, Puxeddu I, Reich R, Levi-Schaffer F, Berkman N. Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts. Ann Allergy Asthma Immunol 2010; 104: 66-72.
83. Xanthou G, Alisaffi T, Semitekolou M, et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nature Med 2007; 13: 570-8.
84. Kohan M, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Enhanced osteopontin expression in a murine model of allergen-induced airway remodelling. Clin Exp Allergy 2007; 37: 1444-54.
85. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofi-broblast differentiation. Circ Res 2008; 102: 319-27.
86. Kohan M, Breuer R, Berkman N. Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am J Resp Cell Mol Biol 2009; 41: 290-6.
87. Leali D, Dell'Era P, Stabile H, et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogen-esis. J Immunol 2003; 71: 1085-93.
88. Puxeddu I, Berkman N, Ribatti D, et al. Osteopontin is expressed and functional in human eosinophils. Allergy 2010; 65: 168-74.
89. White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol 2008; 216: 1-14.
90. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200: 500-3.
91. Muro AF, Moretti FA, Moore BB, et al. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 638-45.
92. Kohan M, Muro AF, Bader R, Berkman N. The extra domain-A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice. J Allergy Clin Immunol 2011; 127: 439-46.
93. Leigh R, Ellis R, Wattie JN, et al. Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med 2004; 169: 860-7.
94. Yang G, Volk A, Petley T, et al. Anti IL-13 monoclonal antibody inhibits airway responsiveness, inflammation and airway remodeling. Cytokine 2004; 28: 224-32.
95. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiological abnormalities and eotaxin production. J Clin Invest 1999; 103: 779-88.
96. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
97. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
98. Folkman J. Endogenous angiogenesis inhibitors. Acta Pathol Micro Immunol Scand 2004; 112: 496-507.
99. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997; 156: 229-33.
100. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
101. Lee CG, Link H, Baluk P, et al. Vascular endothe-lial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10: 1095-103.
102. Walters EH, Soltani A, Reid DW, Ward C. Vascular remodelling in asthma. Curr Opin Allergy Clin Immunol 2008; 8: 39-43.
103. Demoly P, Maly FE, Mautino G, et al. VEGF levels in asthmatic airways do not correlate with plasma extravasation. Clin Exp Allergy 1999; 29: 1390-4.
104. Asai K, Kanazawa H, Otani K, Shiraishi S, Hirata K, Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin Immunol 2002; 110: 571-5.
105. Simcock DE, Kanabar V, Clarke GW, O'Connor BJ, Lee Th, Hirst SJ. Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma. Am J Respir Crit Care Med 2007; 176: 146-53.
106. Abdel-Rahman AM, el-Sahrigy SA, Bakr SI. A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack. Chest 2006; 129: 266-71.
107. Feltis BN, Wignarajah D, Reid DW, Ward C, Harding R, Walters EH. Effects of inhaled fluticasone on ang-iogenesis and vascular endothelial growth factor in asthma. Thorax 2007; 62: 314-19.
108. Olgart Hoglund C, de Blay F, Oster JP, Duvernelle C, Kassel O, Pauli G, Frossard N. Nerve growth factor levels and localisation in human asthmatic bronchi. Eur Respir J 2002; 20: 1110-16.
109. Lazarovici P, Gazit A, Staniszewska I, Marcinkiewicz C, Lelkes PI. 2006; Nerve growth factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane. Endothelium 13: 51-9.
110. Braun A, Appel E, Baruch R, et al. Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma. Eur J Immunol 1998; 28: 3240-51.
111. Solomon A, Aloe L, Peer J, Frucht-Pery J, Bonini S, Levi-Schaffer F. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 1998; 102: 454-60.
112. Makinde T, Murphy RF, Agrawal DK. Immunomodulatory role of vascular endothelial growth factor and angiopoietin-1 in airway remodeling. Curr Mol Med 2006; 6: 831-41.
113. Feltis BN, Wignarajah D, Zheng L, Ward C, Reid D, Harding R, Walters EH. Increased vascular endothelial growth factor and receptors: relationship to angiogen-esis in asthma. Am J Respir Crit Care Med 2006; 173: 1201-7.
114. Kanazawa H, Nomura S, Asai K. Roles of angiopoietin-1 and angiopoietin.2 on airway microvascular permeability in asthmatic patients. Chest 2007; 131: 1035-41.
115. Alagappan VK, Willems-Widyastuti A, Seynhaeve AL, et al. Vasoactive peptides upregulate mRNA, expression and secretion of vascular endothelial growth factor in human airway smooth muscle cells. Cell Biochem Biophys 2007; 47: 109-18.
116. Cruz A, Parnot C, Ribatti D, Corvol P, Gasc JM. Endothelin-1: a regulator of angiogenesis in the chick chorioallantoic membrane. J Vasc Res 2001; 38: 536-45.
117. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothe-lial cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157: 1703-11.
118. Shichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 1997; 30: 1198-203.
119. Spinella F, Garrafa E, Di Castro V, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 2009; 69: 2669-76.
120. Simcock DE, Kanabar V, Clarke GW, et al. Induction of angiogenesis by airway smooth muscle from patients with asthma. Am J Respir Crit Care Med 2008; 178: 460-8.
121. Kulka M, Fukuishi N, Metcalfe DD. Human mast cells synthesize and release angiogenin, a member of the ribonuclease A (RNase A) superfamily. J Leukoc Biol 2009; 86: 1217-26.
122. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
123. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
124. Suzaki Y, Hamada K, Sho M, et al. A potent antian-giogenic factor, endostatin prevents the development of asthma in a murine model. J Allergy Clin Immunol 2005; 116: 1220-7.
125. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418: 426-30.
126. Puxeddu I, Pang YY, Harvey A, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol 2008; 121: 1400-6.
127. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 2005; 37: 628-36.
128. Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 2005; 116: 531-6.
129. Puxeddu I, Berkman N, Ben Efraim N, et al. The role of eosinophil major basic protein in angiogenesis. Allergy 2009; 64: 368-74.
130. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-61.
131. Nissim Ben Efraim AH, Eliashar R, Levi-Schaffer F. Hypoxia modulates human eosinophil function. Clin Mol Allergy 2010; 8: 10.
132. Wen FQ, Kohyama T, Skold CM, et al. Glucocorticoids modulate TGF beta production. Inflammation 2002; 26: 279-90.
133. Meisler N, Keefer KA, Ehrlich HP, Yager DR, Myers-Parrelli J, Cutroneo KR. Dexamethasone abrogates the fibrogenic effect of transforming growth factor beta in rat granuloma and granulation tissue fibroblasts. J Invest Dermatol 1997; 108: 285-9.
134. Johnson PR, Black JL, Carlin S, Ge Q, Underwood PA. The production of extracellular matrix proteins by human passively sensitized airway smooth muscle cells in culture: the effect of beclomethasone. Am J Respir Crit Care Med 2000; 162: 2145-51.
135. Olivieri D, Chetta A, Del Donno M. Effect of short term treatment with low-dose inhaled fluticasone pro-pionate on airway inflammation and remodeling in mild asthma; a placebo-controlled study. Am J Respir Crit Care Med 1997; 155: 1864-971.
136. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159: 1043-51.
137. Lundgren R, Soderberg M, Horstedt P, Stenling R. Morphological studies of bronchial biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1: 883-9.
138. Chetta A, Zanini A, Foresi A. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy 2005; 35: 143742.
139. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. I ncreased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003; 33: 595-9.
140. Feltis BN, Wignarajah D, Reid DW, Ward C, Harding R, Walters EH. Effects of inhaled fluticasone on ang-iogenesis and vascular endothelial growth factor in asthma. Thorax 2007; 62: 314-19.
141. Orsida C, Ward C, Li X, et al. Effect of a long acting beta-2 agonist over three months on airway wall vascular remodelling in asthma. Am J Respir Crit Care Med 2001; 164: 117-121.
142. Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718-28.
143. Laping NJ, Grygielko E, Mathur A. Inhibition of transforming growth factor (TGF) beta 1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity; SB-431542; Mol Pharmacol 2002; 62: 58-64.
144. DaCosta BS, Major C, Laping NJ, Roberts AB. SB-505124; is a selective inhibitor of transforming growth factor-beta type I receptors ALK4: ALK5. Mol Pharmacol 2006; 65: 744-52.
145. Cui Q, Lim SK, Zhao B, Hoffman FM. Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1: Lef1 and CBP. Oncogene 2005; 24: 3864-74.
146. Flanders K. Smad3 as a mediator of the fibrotic response. Int J Exp Path 2004; 85: 47-64.
147. Aschenbrenner JK, Sollinger HW, Becker BN, Hullett DA. 1,25-(OH)(2)D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171-5.
148. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Bld Marrow Transpl 2003; 9: 417-25.
149. Honda K, Marquillies P, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 2004; 113: 882-8.
150. Benayoun L, Letuve S, Druilhe A. Regulation of peroxi-some proliferator-activated receptor gamma expression in human asthmatic airways relationship with proliferation, apoptosis and airway remodeling. Am J Respir Crit Care Med 2001; 164: 1487-94.
151. Brigstock DR. Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): from pharmacological inhibition in-vitro to targeted siRNA, therapy in-vivo. J Cell Commun Signal 2009; 3: 5-18.
152. Unemori EN, Pickford LB, Salles AL. Relaxin induced an extracellular matrix degrading, phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-45.
153. Behera AK, Kumar M, Lockey RF, Mohapatra SS. Adenovirus-mediated interferon gamma gene therapy for allergic asthma involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther 2002; 13: 1697-709.
154. Boguniewicz M, Martin RJ, Martin D. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995; 95: 133-5.
155. Cho JY, Miller M, Baeck KJ, et al. Inhibition of airway remodeling in IL-5 deficient mice. J Clin Invest 2004; 113: 551-60.
156. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7.
157. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
158. Lee SY, Paik SY, Chung SM. Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma. J Microbiol 2005; 43: 11-16.
159. Fujitani Y, Trifilieff A, Tsuyuki S, Coyle AJ, Bertrand C. Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice. Am J Respir Crit Care Med 1997; 155: 1890-4.